Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer (vol 71, pg 297, 2024)

被引：0
|
作者：
Ying, Xixi [1 ,2 ]
Shi, Zheng [3 ,4 ]
Shao, Rongjun [1 ,2 ]
You, Guangxian [2 ]
Song, Zhengbo [1 ,3 ,4 ]
机构：
[1] Zhejiang Chinese Med Univ, Grad Sch, Hangzhou, Zhejiang, Peoples R China
[2] Taizhou Canc Hosp, Dept Radiol & Oncol, Taizhou, Peoples R China
[3] Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Canc Hosp, Dept Clin Trial, Hangzhou, Zhejiang, Peoples R China
来源：
NEOPLASMA | 2024年 / 71卷 / 05期
关键词：
D O I：
10.4149/neo_2024_231104N572COR
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer
    Ying, Xixi
    Shi, Zheng
    Shao, Rongjun
    You, Guangxian
    Song, Zhengbo
    NEOPLASMA, 2024, 71 (03) : 297 - 305
  • [2] Opportunities and challenges of immune checkpoint inhibitors for extensive-stage small-cell lung cancer
    Zhao, Jing
    Zhuo, Xiaoli
    Liu, Lei
    Yang, Zhe
    Fu, Guobin
    CANCER INNOVATION, 2022, 1 (02): : 183 - 193
  • [3] Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)
    Xiaoting Ma
    Shan Wang
    Yujian Zhang
    Huamin Wei
    Jing Yu
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 593 - 606
  • [4] Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)
    Ma, Xiaoting
    Wang, Shan
    Zhang, Yujian
    Wei, Huamin
    Yu, Jing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (02) : 593 - 606
  • [5] Immune checkpoint inhibitors in extensive-stage small cell lung cancer
    Zhang, Tongmei
    JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (03): : 130 - 131
  • [6] Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer
    Li, Han
    Yuan, Shumin
    Wu, Han
    Wang, Yajie
    Ma, Yichen
    Tang, Xiance
    Fu, Xiaomin
    Zhao, Lingdi
    Xu, Benling
    Li, Tiepeng
    Qin, Peng
    You, Hongqin
    Han, Lu
    Wang, Zibing
    CANCER INNOVATION, 2024, 3 (06):
  • [7] Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options
    Zugazagoitia, Jon
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 671 - +
  • [8] Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
    Wang, Chunyu
    Mu, Shuai
    Yang, Xuhui
    Li, Lingling
    Tao, Haitao
    Zhang, Fan
    Li, Ruixin
    Hu, Yi
    Wang, Lijie
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
    Wang, Chunyu
    Jing, Fangfang
    Zhang, Fan
    Tao, Haitao
    Ma, Junxun
    Hu, Yi
    Wang, Lijie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer
    Zhang, Baishen
    Bao, Hejing
    Li, Zhanquan
    Chen, Jing
    Yu, Hui
    Li, Meichen
    Cai, Muyan
    Chen, Likun
    LUNG CANCER, 2025, 199
12345